HLA-C and neoplasm: Past and emerging studies consolidate the utility of conventional T-cells as sources of TCRs strongly reactive to peptide-HLA complexes based on the best-fitting epitopes to transduce PBMCs for developing possible ‘off-the-shelf’ TCRs options for patients with cancer expressing distinct tumor-associated antigens and sharing the respective restricting MHC allele (41, 226–230).